Back to Directory
Lonapegsomatropin
Performance & EnduranceLong-acting growth hormone for pediatric growth hormone deficiency, weekly dosing.
Key Benefits
- ✓Weekly GH for children
- ✓Reduces injection burden
- ✓Treats pediatric GHD
- ✓Improved compliance
- ✓Non-inferior to daily
Dosing Information
Dosage Range
0.24 mg/kg/week
Frequency
Once weekly
Typical Duration
Until growth plates close
Detailed Protocol
Administered via subcutaneous injection once weekly in children with GHD. Dose based on weight. Titrated based on growth response and IGF-1. Prescription only.
About Lonapegsomatropin
Lonapegsomatropin (Skytrofa) is a long-acting prodrug of somatropin (GH) enabling once-weekly administration in children. TransCon technology provides sustained release. FDA-approved for pediatric GH deficiency.
Research Notes
FDA-approved in 2021 for pediatric GHD. First weekly GH for children. Reduces burden from daily injections. Clinical trials showed non-inferiority to daily somatropin.
Potential Side Effects
- •Similar to daily GH
- •Injection site reactions
- •Headache
- •Arthralgia
- •Hypothyroidism
Always consult with a healthcare professional before starting any peptide therapy.